Cetuximab
Cetuximab (Erbitux) is a recombinant chimeric IgG1 monoclonal antibody directed at the extracellular domain of the EGFR, a receptor tyrosine kinase overexpressed or dysregulated in many solid tumors.
Cetuximab (Erbitux) is a recombinant chimeric IgG1 monoclonal antibody directed at the extracellular domain of the EGFR, a receptor tyrosine kinase overexpressed or dysregulated in many solid tumors. It binds domain III and competitively blocks ligand engagement, holding the receptor in its inactive conformation so that the RAS/MAPK and Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) cascades below it are not fired, which suppresses proliferation, angiogenesis, invasion and metastasis. Its IgG1 Fc region adds a second, independent mechanism: antibody-dependent cellular cytotoxicity mediated by natural killer cell populations, which is absent from the fully human IgG2 antibody panitumumab and is one reason the two behave differently despite sharing a target. Originally approved for EGFR-expressing metastatic colorectal cancer without KRAS selection, and for squamous cell carcinoma of the head and neck, it is commonly given with chemotherapy backbones such as FOLFOX or irinotecan hydrochloride-containing regimens.
Its clinical use is now defined by what lies downstream of the receptor. Activating mutations in KRAS or NRAS make blockade at the receptor irrelevant, so extended RAS testing is required before treatment and BRAF V600E predicts poor benefit — the restriction that was added after approval and that turned an unselected therapy into a biomarker-directed one. Primary tumor location refines this further: left-sided colorectal cancers respond substantially better than right-sided ones, reflecting different underlying biology rather than anatomy as such. Two toxicities are characteristic — an acneiform rash whose severity correlates with response, since it reflects the same receptor being blocked in skin, and infusion reactions driven by pre-existing IgE against the galactose-α-1,3-galactose sugar on the murine portion of the antibody, which are concentrated in particular geographic regions.
Resistance, intrinsic and acquired, remains the central limitation, typically through emergence of RAS-mutant subclones detectable in circulating tumor DNA before radiographic progression. Cetuximab also serves as a benchmark anti-EGFR antibody against which newer modalities are compared, and as a well-characterized reference molecule in analytical and biopharmaceutical development alongside trastuzumab and bevacizumab.
Where the papers sit
10 papers from the last 6 months study cetuximab directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 4 observational · 2 human data · 3 preclinical · 1 unclassified
Themes 3 themes
-
Colorectal Cancer Treatment
Colorectal cancer therapy is being assessed through treatment safety, resistance biology, prognosis, access, and cost. Targeted therapy combined with FOLFOX or FOLFIRI generates adverse-event signals, while ZDHHC9-driven lipid reprogramming and ACSL3 palmitoylation emerge as mechanisms of cetuximab resistance. Tumor-educated platelet signatures aim to improve outcome prediction, and encorafenib is evaluated for the economic management of BRAF V600E-mutant disease. Treatment delivery also remains important, with chemoport-related venous stenosis documented as a complication.
5 papers · 50%
-
Head and Neck Cancer Therapy
Head and neck squamous cell carcinoma treatment is moving across neoadjuvant chemotherapy, real-world sequencing, immunotherapy, and targeted resistance management. Paclitaxel, carboplatin, and cetuximab are being tested before definitive treatment, while pembrolizumab features in recurrent or metastatic treatment pathways. An EGFR S442 ectodomain mutation confers cetuximab resistance, with trastuzumab-deruxtecan offering a potential ERBB2-directed rescue strategy. Photoimmunotherapy also remains an emerging treatment area requiring practical photosensitivity assessment.
4 papers · 40%
-
α-Gal Allergy Antibody Therapy
α-Gal allergy research is focusing on antibody control of allergen-driven IgE responses. Human monoclonal antibodies targeting α-Gal can restrict IgE engagement with α-Gal-containing allergens. The proposed effect is reduced activation of basophils and other allergic effector pathways. This work supports antibody-based strategies for limiting α-Gal syndrome, but clinical therapeutic benefit remains to be established.
1 papers · 10%
Papers
The 10 papers from the last 6 months that study cetuximab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Colorectal Cancer Treatment (5)
- Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study. Medicine · 6 Nov 2026 PMID 42994833
- ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
- Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response. iScience · 30 Jun 2026 PMID 42375537
- Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China. The pharmacogenomics journal · 25 May 2026 PMID 42185244
- Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. PloS one · 20 May 2026 PMID 42160312
Head and Neck Cancer Therapy (4)
- Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study). Oral oncology · 18 Aug 2026 PMID 42612404
- Utility of a Simplified Irradiator for Photosensitivity Testing in Head and Neck Photoimmunotherapy. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379786
- Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
- EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
α-Gal Allergy Antibody Therapy (1)
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. The Journal of clinical investigation · 1 Sept 2026 PMID 42677844
By study type
Observational studies and case reports (4)
- Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study). Oral oncology · 18 Aug 2026 PMID 42612404
- Utility of a Simplified Irradiator for Photosensitivity Testing in Head and Neck Photoimmunotherapy. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379786
- Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
- Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. PloS one · 20 May 2026 PMID 42160312
Human data, design not indexed (2)
- Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study. Medicine · 6 Nov 2026 PMID 42994833
- Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China. The pharmacogenomics journal · 25 May 2026 PMID 42185244
Preclinical: animal, cell and lab studies (3)
- ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. The Journal of clinical investigation · 1 Sept 2026 PMID 42677844
- EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
Unclassified: not yet indexed with MeSH (1)
- Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response. iScience · 30 Jun 2026 PMID 42375537
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-03 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.